Metabolic syndrome obesity
Conditions
Interventions
All patient will adhere to the mediterranean for the total duration of the
study with guidance of a dietitian and/or investigator.
Patients will be treated with infusion of either allogenic (lean he
during the procedure mucosal biopsies from small intestine will be taken.
Correct position of the tube is checked with an abdominal X-ray.
3. Thereafter, bowel lavage with 2-3 liters of Clean Prep th
Gut microbiota
Mediterranean diet
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Patients: Male obese (BMI > 30) subjects 21 to 65 years-old With at least 3 out of 5 metabolic syndrome criteria (fasting plasma glucose * 5.6 mmol/l, triglycerides * 1.7 mmol/l, waist-circumference > 102 cm, HDL-cholesterol
Exclusion criteria
Exclusion criteria: Patients: - Use of any medication, including proton pomp inhibitors and antibiotics in the past three months - Cholecystectomy - A history of cardiovascular event (MI or pacemaker implantation) - (expected) prolonged compromised immunity (due to recent cytotoxic chemotherapy or HIV infection with a CD4 count
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoints are changes in fecal, intestinal (biopsies) and oral microbiota composition and (the relation to) peripheral /hepatic insulin sensitivity (stable isotope based hyperinsulinemic euglycemic clamp and resting energy expenditure) at baseline and 6 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are changes in postprandial plasma lipids (mixed meal test) and subcutaneous adipose tissue inflammation (biopt) at baseline and 6 weeks. Finally, we will study effect on plasma and 24 feces and 24 urine metabolites at baseline, after 3 and 6 weeks | — |
Countries
The Netherlands
Outcome results
None listed